GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PharmAbcine Inc (XKRX:208340) » Definitions » EV-to-EBITDA

PharmAbcine (XKRX:208340) EV-to-EBITDA : -9.01 (As of Sep. 27, 2024)


View and export this data going back to 2018. Start your Free Trial

What is PharmAbcine EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, PharmAbcine's enterprise value is ₩74,575.1 Mil. PharmAbcine's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-8,273.7 Mil. Therefore, PharmAbcine's EV-to-EBITDA for today is -9.01.

The historical rank and industry rank for PharmAbcine's EV-to-EBITDA or its related term are showing as below:

XKRX:208340' s EV-to-EBITDA Range Over the Past 10 Years
Min: -67.02   Med: -5.85   Max: -0.69
Current: -9.01

During the past 7 years, the highest EV-to-EBITDA of PharmAbcine was -0.69. The lowest was -67.02. And the median was -5.85.

XKRX:208340's EV-to-EBITDA is not ranked
in the Biotechnology industry.
Industry Median: 8.79 vs XKRX:208340: -9.01

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-09-27), PharmAbcine's stock price is ₩2915.00. PharmAbcine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was ₩-304.000. Therefore, PharmAbcine's PE Ratio (TTM) for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).


PharmAbcine EV-to-EBITDA Historical Data

The historical data trend for PharmAbcine's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PharmAbcine EV-to-EBITDA Chart

PharmAbcine Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial -46.30 -11.88 -4.38 -2.25 -8.44

PharmAbcine Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.86 -0.95 -8.44 -7.09 -11.44

Competitive Comparison of PharmAbcine's EV-to-EBITDA

For the Biotechnology subindustry, PharmAbcine's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PharmAbcine's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmAbcine's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PharmAbcine's EV-to-EBITDA falls into.



PharmAbcine EV-to-EBITDA Calculation

PharmAbcine's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=74575.083/-8273.742
=-9.01

PharmAbcine's current Enterprise Value is ₩74,575.1 Mil.
PharmAbcine's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-8,273.7 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PharmAbcine  (XKRX:208340) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

PharmAbcine's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2915.00/-304.000
=At Loss

PharmAbcine's share price for today is ₩2915.00.
PharmAbcine's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩-304.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).

Please read Which price ratio outperforms the enterprise multiple?


PharmAbcine EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PharmAbcine's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PharmAbcine Business Description

Traded in Other Exchanges
N/A
Address
70, 2, 2nd Floor, KT Daedeok 2 Research Center, Jeonmin-dong, Yuseong-dong, Daejeon Metropolitan City, KOR, 1689
PharmAbcine Inc is a clinical stage biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.

PharmAbcine Headlines

No Headlines